Exalenz Bioscience Ltd (EXEN) - Product Pipeline Analysis, 2018 Update

  • ID: 4267324
  • Company Profile
  • 38 pages
  • GlobalData
1 of 5

FEATURED COMPANIES

  • Kibion AB
  • MedMira Inc
  • Meridian Bioscience Inc
  • MORE
Summary

Exalenz Bioscience Ltd (Exalenz) carries out the development and commercialization of advanced medical systems for a range of gastrointestinal (GI) tract and liver disorders. The company harnesses its BreathID technology platform for assessment and monitoring of functional diseases. Its flagship product, BreathID Hp is a US FDA approved and CE marked urea breath test for diagnosing, monitoring and managing gastric Helicobacter pylori (H. pylori) infection in adults. It also offers BreathID 13C-methacetin breath test, a non-invasive point of care tool measures the microsomal function of the liver. It works in collaboration with various clinical and industrial partners in Europe, Asia, the US and Israel. Exalenz is headquartered in Modiin, Israel.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Exalenz Bioscience Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Kibion AB
  • MedMira Inc
  • Meridian Bioscience Inc
  • MORE
  • Exalenz Bioscience Ltd Company Overview
  • Exalenz Bioscience Ltd Company Snapshot
  • Exalenz Bioscience Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • Exalenz Bioscience Ltd - Pipeline Analysis Overview
  • Business Description
  • Exalenz Bioscience Ltd - Key Facts
  • Exalenz Bioscience Ltd - Major Products and Services
  • Exalenz Bioscience Ltd Pipeline Products by Development Stage
  • Exalenz Bioscience Ltd Ongoing Clinical Trials by Trial Status
  • Exalenz Bioscience Ltd Pipeline Products Overview
  • BreathID Methacetin Breath Test - Acute Liver Failure
  • BreathID Methacetin Breath Test - Acute Liver Failure Product Overview
  • BreathID Methacetin Breath Test - Acute Liver Failure Clinical Trial
  • BreathID Methacetin Breath Test - NASH
  • BreathID Methacetin Breath Test - NASH Product Overview
  • BreathID Methacetin Breath Test - NASH Clinical Trial
  • BreathID Test - Chronic Liver Disease
  • BreathID Test - Chronic Liver Disease Product Overview
  • BreathID Test - Chronic Liver Disease Clinical Trial
  • BreathID Test - Hepatocellular Carcinoma
  • BreathID Test - Hepatocellular Carcinoma Product Overview
  • BreathID Test - Pancreatitis
  • BreathID Test - Pancreatitis Product Overview
  • BreathID Test - Portal Hypertension
  • BreathID Test - Portal Hypertension Product Overview
  • Exalenz Bioscience Ltd - Key Competitors
  • Exalenz Bioscience Ltd - Key Employees
  • Exalenz Bioscience Ltd - Key Employee Biographies
  • Exalenz Bioscience Ltd - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Recent Developments
  • Exalenz Bioscience Ltd, Recent Developments
  • Apr 30, 2018: Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer
  • Mar 13, 2018: Exalenz Bioscience’s BreathID Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients
  • Mar 12, 2018: Exalenz Announces Fourth Quarter and Full Year 2017 Financial Results
  • Jan 30, 2018: Carestream’s Vue Motion Universal Viewer Earns 2018 KLAS Category Leader Award
  • Jan 23, 2018: Exalenz Bioscience Announces Positive Clinical Trial Results for the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients
  • Jan 01, 2018: A New Perspective on MR with Philips
  • Aug 17, 2017: Exalenz Bioscience Launches Automated BreathID Hp Lab Urea Breath Testing System For Helicobacter pylori Detection
  • Apr 18, 2017: Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress 2017
  • Nov 01, 2016: Exalenz Bioscience Receives FDA Marketing Clearance for its Laboratory System in the United States
  • Mar 14, 2016: Exalenz Biosciences Announces Collaboration with ALF Study Group to use BreathID to Monitor Patients with Acute Liver Failure
  • Appendix
  • Methodology
  • About
  • Contact
  • Disclaimer
List of Tables
  • Exalenz Bioscience Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • Exalenz Bioscience Ltd Pipeline Products by Equipment Type
  • Exalenz Bioscience Ltd Pipeline Products by Indication
  • Exalenz Bioscience Ltd Ongoing Clinical Trials by Trial Status
  • Exalenz Bioscience Ltd, Key Facts
  • Exalenz Bioscience Ltd, Major Products and Services
  • Exalenz Bioscience Ltd Number of Pipeline Products by Development Stage
  • Exalenz Bioscience Ltd Pipeline Products Summary by Development Stage
  • Exalenz Bioscience Ltd Ongoing Clinical Trials by Trial Status
  • Exalenz Bioscience Ltd Ongoing Clinical Trials Summary
  • BreathID Methacetin Breath Test - Acute Liver Failure - Product Status
  • BreathID Methacetin Breath Test - Acute Liver Failure - Product Description
  • BreathID Methacetin Breath Test - Acute Liver Failure - 13C-Methacetin Breath Test for the Prediction of Outcome in Acute Liver Failure
  • BreathID Methacetin Breath Test - Acute Liver Failure - A Multi-center Trial to Study Acute Liver Failure in Adults
  • BreathID Methacetin Breath Test - Acute Liver Failure - Clinical Study of the BreathID LF System to Train the Algorithm for the ¹³C-methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients with Compensated Liver Cirrhosis
  • BreathID Methacetin Breath Test - Acute Liver Failure - The Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation; A Retrospective Analysis
  • BreathID Methacetin Breath Test - NASH - Product Status
  • BreathID Methacetin Breath Test - NASH - Product Description
  • BreathID Methacetin Breath Test - NASH - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension
  • BreathID Methacetin Breath Test - NASH - Study on Clinical Utility of BreathID in Diagnosis of Nonalcoholic Steatohepatitis
  • BreathID Test - Chronic Liver Disease - Product Status
  • BreathID Test - Chronic Liver Disease - Product Description
  • BreathID Test - Chronic Liver Disease - 13C-Methacetin Breath Test for the Prediction of Outcome in Acute Liver Failure
  • BreathID Test - Hepatocellular Carcinoma - Product Status
  • BreathID Test - Hepatocellular Carcinoma - Product Description
  • BreathID Test - Pancreatitis - Product Status
  • BreathID Test - Pancreatitis - Product Description
  • BreathID Test - Portal Hypertension - Product Status
  • BreathID Test - Portal Hypertension - Product Description
  • Exalenz Bioscience Ltd, Key Employees
  • Exalenz Bioscience Ltd, Key Employee Biographies
  • Exalenz Bioscience Ltd, Subsidiaries
  • Glossary
List of Figures
  • Exalenz Bioscience Ltd Pipeline Products by Equipment Type
  • Exalenz Bioscience Ltd Pipeline Products by Development Stage
  • Exalenz Bioscience Ltd Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Serim Research Corporation
  • Meridian Bioscience Inc
  • MedMira Inc
  • Kibion AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll